Soligenix Gets a Buy Rating from Maxim Group

Maxim Group analyst Jason McCarthy maintained a Buy rating on Soligenix (NASDAQ: SNGX) today and set a price target of $5. The company’s shares closed on Friday at $1.57, close to its 52-week low of $1.45.

McCarthy commented:

“Soligenix will be presenting preclinical and proof of concept clinical data for Dusquetide (Innate Defense Regulator, see below) in the treatment of infectious disease at the upcoming American Society of Microbiology Microbe Conference (6/7-6/11).”

According to TipRanks.com, McCarthy is a 5-star analyst with an average return of 12.6% and a 45.8% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, SELLAS Life Sciences Group Inc, and ContraVir Pharmaceuticals Inc.

Soligenix has an analyst consensus of Moderate Buy, with a price target consensus of $3.85.

See today’s analyst top recommended stocks >>

The company has a one-year high of $3.70 and a one-year low of $1.45. Currently, Soligenix has an average volume of 160.1K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Soligenix, Inc. is a clinical stage biopharmaceutical company, which engages in developing products to treat serious gastrointestinal diseases. It operates through the BioTherapeutics and Vaccines or BioDefense segments.